Publications A/Prof David van der Poorten

Associate Professor van der Poorten has published widely in the medical literature and continues to be active in teaching and research.

Summaries of research output can be found on:

Google Scholar

Research Gate

Publications are listed below by topic.

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

C Haifer, CR Kelly, S Paramsothy, D Andresen, LE Papanicolas, D van der Poorten, Rupert Leong. Gut 2020. 69 (5), 801-810
 

The Gut Microbiome in Health and Illness

R Trieu, D van der Poorten. Medicine Today 2021. 22 (3), 44-50
 

The gut microbiome

M. Sidhu, D. van der Poorten. Australian family Physician 2017 46(4), 206-211

 

Fecal microbiota transplantation for recurrent Clostridium difficile infection: When regulatory affairs do not keep pace with evidence-based medicine

SP Costello, D Van der Poorten, JM Andrews. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017. 32, 156-157

 

Do patients with non-alcoholic fatty liver disease require tailored surveillance for colorectal neoplasms?

P Suo, W Siow, D Van Der Poorten, J George, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 2018. 33, 72-72
 

The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice.

van der Poorten D, Katelaris P. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1537-42. Epub 2007 Sep 28. Impact factor 3.71

 

Feasibility and safety of overtubes for PEG-tube placement in patients with head and neck cancer.

Musumba CO, Hsu J, Ahlenstiel G, Tutticci NJ, Nanda KS, van der Poorten D, Lee EY, Kwan V. Gastroenterol Res Pract. 2015;2015:612610.

 

Levodopa-carbidopa intestinal gel infusion improves motor performance and quality of life in patients with advanced Parkinson’s disease.

Florence Ching-Fen Chang, Vu Kwan, D Van der Poorten, Neil Mahant, Nigel Wolfe, Ainhi Ha, Jane Griffith, David Tsui, Samuel Kim, Victor SC Fung. Journal of Clinical Neuroscience 2014, 21 (11), 2033

 

Compounded levofloxacin triple therapy for treatment resistant Helicobacter Pylori.

V Gupta, SN Loch, D Van der Poorten. J Gastro Hep. 2014 Oct; 29, 138-138

Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery

A Yang, M Nguyen, I Ju, A Brancatisano, B Ryan, D van der Poorten. Scientific reports 2021. 11 (1), 1-7
 

Obesity, gastrointestinal cancer and the role of visceral fat

D van der Poorten. Translational Gastrointestinal Cancer. 2014 3 (3), 127-129

 

Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?

van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, Wu LE, McLeod D, Bugianesi E, Komuta M, Roskams T, Liddle C, Hebbard L, George J. Hepatology. 2013 Jun;57(6):2180-8. doi: 10.1002/hep.26072. Epub 2013 Jan 18.

 

Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease.

Vongsuvanh R, George J, McLeod D, van der Poorten D. J Hepatol. 2012 Aug;57(2):392-8. Epub 2012 Apr 17.

Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, Ching HL, Bulsara M, Jeffrey GP. J Gastroenterol Hepatol. 2011 Oct;26(10):1536-43.

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.

Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J.
Hepatology. 2011 Oct;54(4):1208-16. doi: 10.1002/hep.24491. Epub 2011 Aug 9.

Adipocytokine levels in Non-Alcoholic Fatty Liver Disease; Author Reply.

van der Poorten D, Milner KL, Chisholm DJ, George J. Hepatology, 2009 Jul;50(1):327-328. Impact factor 11.355

Adipocyte Fatty Acid Binding Protein levels relate to inflammation and fibrosis in Non Alcoholic Fatty Liver Disease.

Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ, George J.
Hepatology, 2009 Jun;49(6):1926-34. Impact factor 11.355

Nonalcoholic steatohepatitis is frequently accompanied by metabolic diseases; Author Reply.

van der Poorten D, George J.
Hepatology, 2008 Nov;48(5):1729 Impact factor 11.355

Non-Alcoholic Steatohepatitis: concepts on pathogenesis and therapy.

George J, van der Poorten D.
In Falk 163: Chronic Inflammation of Liver and Gut. Eds. Adler, Fan, Jia, LaRusso, Owyang. 2008.

Current and novel therapies for the treatment of NASH. (Review)

van der Poorten D, George J.
Hepatology International, 2007 Sep: 1(3):342-354

Visceral fat: a key mediator of steatohepatitis in metabolic liver disease.

van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J.
Hepatology, 2008 Aug;48(2):449-57 Impact factor 11.355

 

Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion

M Ramezani-Moghadam, J Wang, V Ho, TJ Iseli, B Alzahrani, A Xu,  D Van der Poorten, L Qiao, J George, L Hebbard. Journal of Biological Chemistry, 2015 jbc. M114. 598011

 

NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis.

Vi Nguyen, Rob Zielinski, Paul Harnett, Katherine Miller, Henry Chan, Nikitha Vootakuru, Priya Acharya, Montaha Khan, Oliver Gibbs, Sarika Gupta, Anjla Devi, Shani Phillips, Jacob George, David van der Poorten.
ISRN Hepatology 09/2013; 2013. DOI:10.1155/2013/959474

 

Visceral adiposity in gastrointestinal and hepatic carcinogenesis.

Vongsuvanh R, George J, Qiao L, van der Poorten D.
Cancer Lett. 2013 Mar 1;330(1):1-10. doi: 10.1016/j.canlet.2012.11.038. Epub 2012 Nov 29. Review.

 

Effect of Adipokines on liver disease in females.

van der Poorten D, Milner KL, George J.
In; Female Hepatology: Impact of female sex against progression of liver disease. Shimizu I. 2008.

 

Mechanisms of fibrosis: Hepatitis C and NASH

van der Poorten D, George J.
Clin Liver Dis. 2008 Nov;12(4):805-24, ix

 

Liver disease in adolescents; A cohort study of high risk individuals.

van der Poorten D, Kenny DT, Butler T, George J.
Hepatology. 2007 Dec;46(6):1750-8. Impact factor 11.355

 

A twenty year audit of percutaneous liver biopsy in a major Australian teaching hospital.

van der Poorten D, Kwok A, Lam T, Ridley L, Ngu MC, Jones DB, Lee AU.
Intern Med J. 2006 Nov;36(11);692-99. Editorialised. Impact factor: 2.027

 

Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.

O'Connor KS, Parnell G, Patrick E, Ahlenstiel G, Suppiah V, van der Poorten D, Read SA, Leung R, Douglas MW, Yang JY, Stewart GJ, Liddle C, George J, Booth DR. Genes Immun. 2013 Dec 12. doi: 10.1038/gene.2013.66. [Epub ahead of print]

 

IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis.

O'Connor KS, Ahlenstiel G, Suppiah V, Schibeci S, Ong A, Leung R, van der Poorten D, Douglas MW, Weltman MD, Stewart GJ, Liddle C, George J, Booth DR. Innate Immun. 2013 Sep 17. [Epub ahead of print]

 

Hepatitis C virus induces the cannabinoid receptor 1.

van der Poorten D, Shahidi M, Tay E, Sesha J, Tran K, McLeod D, Milliken JS, Ho V, Hebbard LW, Douglas MW, George J.
PLoS One. 2010 Sep 17;5(9). pii: e12841.

 

Chronic Hepatitis C is Associated with Peripheral rather than Hepatic Insulin Resistance.

Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, Zekry A, Weltman M, Fragomeli V, George J, Chisholm DJ.
Gastroenterology. 2009 Dec 3. [Epub ahead of print] Impact Factor 12.6

 

Prevalence of and risk factors for hepatitis C in Aboriginal and non-Aboriginal adolescent offenders.

van der Poorten D, Kenny DT, George J.
Med J Aust. 2008 May 19;188(10):610-4. Impact factor: 3.32

Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine resistant Hepatitis B.

van der Poorten D, Prakoso E, Khoo TL, McCaughan GC, Ngu MC, Strasser SI, Lee AU. J Gastroenterol Hepatol. 2007 Sep;22(9):1500-5. Epub 2007 Aug 6 Impact factor: 2.275

Subacute Upper GI Bleeding Due To Infected Aortic Graft with Aorto-Duodenal Fistula

B Jideh, TH Cho, L Yuen, D van der Poorten
Journal of Gastrointestinal Surgery. 2018. 22 (11), 1987-1988

Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with heterozygous Factor V Leiden mutation: a case report.

Garcia MC, Ahlenstiel G, Mahajan H, van der Poorten D.
J Med Case Rep. 2015 Oct 1;9(1):210. doi: 10.1186/s13256-015-0705-6

Congenital analbuminaemia diagnosed in adulthood in an Australian family.

Berlund LJ, van der Poorten DK, Caridi G, Campagnoli M, Minchiotti L.

Pathology 2015, Aug;47(5):492-4

Acute necrotizing pancreatitis, gastric ischemia, and portal venous gas complicating intragastric balloon placement.

Vongsuvanh R, Pleass H, van der Poorten D.
Endoscopy. 2012;44 Suppl 2 UCTN:E383-4. doi: 10.1055/s-0032-1310146. Epub 2012 Nov 8.

Hepatic lesions and eosinophilia in an urban dweller.

Sivagnanam S, van der Poorten D, Douglas MW.
Liver Int. 2013 Aug 1. doi: 10.1111/liv.12281. [Epub ahead of print]

Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation.

Nguyen V, Gurney H, van der Poorten D.
J Clin Oncol. 2011 Jan 10;29(2):e21-3. Epub 2010 Oct 12. Impact Factor 17.9

A maxiallary mass in a HBV-cirrhotic patient.

Nguyen V, George J, van der Poorten D.
Liver Int. 2012 Jul;32(6):988. Epub 2012 Mar 1.